Familial meningioma is genetically heterogeneous, with three susceptibility genes documented in the packet: MN1, NF2, and PDGFB, each located on chromosome 22. The condition follows an autosomal dominant inheritance pattern. The multi-gene architecture indicates that pathogenic variants in any of these three chromosome 22 loci may underlie heritable meningioma predisposition. The condition's genetic classification is represented in OMIM entry 607174.

The packet records MN1, NF2, and PDGFB as genes with documented validity associations for familial meningioma, all mapped to chromosome 22. Identification of a germline pathogenic variant in one of these susceptibility loci, in the context of a familial meningioma presentation, constitutes the genetic basis for hereditary classification. The condition is registered across multiple ontologies: OMIM:607174, GARD:18385, and MESH:C537443. No consensus diagnostic criteria specific to familial meningioma are documented in the current packet sources.

Active clinical trial investigation in the meningioma disease space encompasses pharmacological and imaging-based strategies. Among the 10 trial records detailed in the packet, documented approaches include a Phase 2 multicenter study evaluating vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib in progressive meningiomas (NCT02523014; Alliance for Clinical Trials in Oncology; estimated completion 2028); an early-phase study evaluating panitumumab-IRDye800 as an optical imaging agent for intracranial lesion detection during neurosurgical procedures (NCT07493447; initiated July 2026); and a Phase 1 feasibility study of hyperpolarized MRI in meningioma patients (NCT06014905). Drug therapy and procedural interventions are among the documented trial intervention categories across the 86 registered trials in this disease space. No FDA-approved treatments specific to familial meningioma are captured in the current packet.

Detailed prognostic data specific to familial meningioma as a distinct hereditary entity are not captured in the current packet. The condition is characterized by heritable tumor predisposition with autosomal dominant transmission. Packet fields do not include data on tumor multiplicity rates, recurrence characteristics, or long-term outcome figures distinguishing the familial form from sporadic meningioma.

The published literature associated with familial meningioma and related meningioma entities encompasses 198 classified publications, with basic science and preclinical research representing the dominant type. The corpus includes biomarker-focused and gene therapy publications, 24 case reports, and 38 review articles; publications linked to recent clinical trial activity are also represented. Active investigational effort spans 86 registered trials, reflecting sustained research across molecular, imaging, and pharmacological domains. The multi-gene heterogeneity of this condition — involving MN1, NF2, and PDGFB on chromosome 22 — is consistent with the broad basic science orientation of the publication landscape.